Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more.
Luke Timmerman
Verified
Biotech journalist. Founder @TimmermanReport.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Luke Timmerman
A Wearable Continuous Immune Monitor: Shana Kelley on The Long Run
Shana Kelley is today’s guest on The Long Run. Shana is a professor of chemistry at Northwestern University and the president of the Chan Zuckerberg Biohub in Chicago. Shana Kelley, professor of chemistry, Northwestern University; president, Chan Zuckerberg Biohub Chicago One of the cool projects she oversees is for a continuous wearable immune monitor. It’s inspired by continuous glucose monitors that have changed the way diabetes is treated and managed.
The Dawning Age of Biology
David Roblin, CEO, Relation Therapeutics In 2012, Jack Scannell, a pharma industry expert, coined the term “EROOM’s law.” This was a vivid way to contrast the declining rate of productivity in drug discovery with the rapid acceleration in computing power that became known after the 1960s as Moore’s law. Eroom’s law stated that the number of new drugs approved per billion US dollars spent on R&D has halved roughly every 9 years since 1950, an 80-fold decrease in inflation-adjusted terms.
The Best AI Health Innovators Have a Feel for People
Abba Eban observed in 1967 that wisdom tends to arrive only after all other alternatives have been exhausted. Happily, some of the most thoughtful innovators in AI and health seem to be getting there. Over the last several weeks I’ve had an unusual opportunity to speak before and engage with audiences of investment bankers, investors, operators, and even political scientists, all of whom were interested in the same basic question: what will AI mean for healthcare and life sciences?
RevMed’s Rollout, Yosemite Invests in Cancer & Servier’s Phase III Whiff
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more.
The AI Moment in Drug Discovery: Daphne Koller on The Long Run
Daphne Koller is today’s guest on The Long Run. Daphne is the founder and CEO of South San Francisco-based Insitro. It’s one of what you could call the first-generation companies that uses AI to speed up and improve drug discovery. Insitro was founded in 2018 and has secured $750 million in funding from venture capital firms and through partnerships with big drugmakers that include Bristol Myers Squibb, AstraZeneca, and Gilead Sciences.
AI and Tocqueville at Harvard
I found myself this week back on my undergraduate campus, giving a seminar about “AI, Health, and Agency” for, of all things, Harvard’s Program in Constitutional Government, invited by Professor (emeritus) Harvey C. Mansfield, who at 94, remains sharper than most of us are or likely ever were. He is not only one of the university’s most distinguished scholars, but also, famously, one of its only (openly) conservative faculty members — and also one of the most demanding.
Anthropic Makes Noise, Silence Gets Bought, & GSK Gets HepB OK
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more.
Creating PROTACs and RIPTACs: Tim Shannon on The Long Run
Tim Shannon is today’s guest on The Long Run. Tim is a general partner at Canaan Partners. He was a pulmonary and critical care physician in the early part of his career, before moving over to R&D leadership in industry, and then eventually into venture capital investing. Tim Shannon, general partner, Canaan Partners Tim got started as a VC during the Great Financial Crisis. That may not sound good, but it was the beginning of a biotech venture capital boom.
BMS Hits IPF Goal, Iambic Goes Public & AZ Invests in Insitro
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more.
AAV Gene Therapy: What It Will Take To Get Through the Wilderness
Richard Wilson, SVP, Primary Focus Lead – Genetic Regulation – Astellas Pharma; Vice Chair, Alliance for Regenerative Medicine When Luke first asked for my perspective on the state of AAV gene therapy over the summer, he asked me “Will AAV ever deliver on its early promise? Be safe? Be commercially successful?”. After ruminating for a while, I settled on the Stockdale paradox (as chronicled in Jim Collins’ Good to Great) as the best description of where we stand.
Biotech IPO Scorecard: Triple the Action in 2026
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more.
Merck Bets on KRAS Drug, Kodiak Hunts Down Regeneron, & Lycia Preps for IPO
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more.
Touch, Pain, and the Edge of Neuroscience: Ardem Patapoutian on The Long Run
Ardem Patapoutian is today’s guest on The Long Run. Ardem is a professor of neuroscience at Scripps Research in San Diego, and an investigator with Howard Hughes Medical Institute. His lab is focused on ion channels on the surface of cells that sense mechanical force, and how those signals are translated into our sense of touch, pain, and other basic bodily functions.
Arboretum Gets $30M to Expand Molecular Dx for Healthcare & Drug Discovery
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more.
Enveda Cashes In, Otsuka Hits ALS Goal, & Viking Braces for GLP-1 Battle
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more.
Long-Lasting Antibodies for Immune Diseases: Cameron Turtle on The Long Run
Cameron Turtle is today’s guest on The Long Run. Cameron Turtle, CEO, Spyre Therapeutics Cameron is the CEO of Waltham, Mass.-based Spyre Therapeutics. The company is developing antibody drug candidates that are engineered to be longer-lasting than today’s drugs for immune disorders. This means patients could take fewer injections and the drugs should stay stable in the bloodstream to keep the disease under control longer.
Scholar Rock Gets FDA OK, Reverse Mergers Continue & Novartis Bets on Brain Delivery
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more.
Novartis’ Rough Week, AstraZeneca’s Better Week, & GV Life Sciences Leader Moves On
Luke Timmerman, founder & editor, Timmerman Report Sometimes drug candidates fail in the most surprising and painful ways. Even after everything looks good in early and mid-stage clinical trials, and with capable hands on the wheel. Ask Novartis. Two weeks ago, few would have predicted the back-to-back Phase III failures of Novartis’ lipoprotein A-directed oligonucleotide for cardiovascular disease and the antibody oligonucleotide conjugate for myotonic dystrophy type 1 (DM1).
Drugs That Go Where None Could Before: Mathai Mammen on The Long Run
Mathai Mammen is today’s guest on The Long Run. Mathai is the CEO of Cambridge, Mass.-based Parabilis Medicines. The company has a platform for making drugs that hit elusive biological targets known as drivers of disease. Parabilis attacks them with alpha-helical peptide drug candidates that can get inside cells and bind with relatively flat and smooth surfaces of proteins. It pursues these targets which conventional small molecules and biologics haven’t been able to hit.
Alumis & BioNTech Stumble, Lilly Buys Merida, & Takeda’s Latest FDA Approval
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more.
IYKYK: Leave the Vortex, Take the Attention
It’s not just your kids who aspire to become influencers. Attracting attention –- often through provocative content delivered through social media at high volume –- can seem increasingly like a business imperative, as the a16z co-founders have described (here, here) and, in the case of Andreessen, unhesitatingly embraced. The Attention Imperative But they’re not alone; many physicians, researchers, and policy wonks are gamely experimenting with short video content.
RevMed’s Watershed, Roivant Goes Commercial, & Roche’s Blood Test for Alzheimer’s
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more.
A Vaccine for Epstein-Barr Virus: Gary Nabel on The Long Run
Gary Nabel is today’s guest on The Long Run. Gary is the CEO of Weston, Mass.-based ModeX Therapeutics. The company has a platform for making multi-specific biologics into vaccines and cancer treatments. ModeX was founded in 2020, building on work that started at Sanofi when Nabel was the chief scientific officer there. Gary Nabel, co-founder and CEO, ModeX Therapeutics The initial application of this technology, currently in clinical trials, is for a vaccine against Epstein-Barr Virus.
Moderna’s Home Run, Amylyx Bounces Back, & Enveda Advances Workout-in-a-Pill
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more.
9 Young Scientists to Watch: the Timmerman Traverse Fellows at Damon Runyon
Our community’s steadfast support of science is more important than ever given the tenuous state of federal research funding. Teams of biotech executives and investors have raised $3.9 million for high-risk/high-reward cancer research since 2024 as part of the Timmerman Traverse for Damon Runyon Cancer Research Foundation. The Traverse has created fun outdoor experiences and lasting friendships.
Harell Data Debuts With $15M To Change Incentives, Speed Up AI Drug Discovery
The Protein Data Bank was the unsung hero that made AlphaFold possible. For decades, the structural biologists, biochemists and others who put carefully curated protein structures in the public domain laid down the conditions for AI to eventually do something useful – predicting protein structures in this case. Those scientists never got a nickel. This is just one of many examples in which AI model builders hoovered up public data for free and now are making their fortunes.
The Narrative Machine: What AI Really Adds to Personal Health Data
For years, the Quantified Self movement had a stubborn problem: our devices became increasingly good at generating data but remained remarkably poor at telling us what any of it meant. Generative AI now dangles a tantalizing possibility: that it can tease genuinely useful personal insights from all those measurements and hand them back to us in a form we can immediately understand and readily apply.
The Other Side of Bayes: Rethinking False Positives in Health Screening
Imagine screening 10,000 apparently healthy people for a disease that affects one person in a thousand. Let’s further assume the test is fairly good: 99% sensitive and 99% specific. (In case it’s been a while, this means the test detects 99% of true cases and correctly exonerates 99% of people without disease.) Ten of those 10,000 people will actually have the disease –- that’s just the prevalence of the condition in the population. The test will identify essentially all of them.
AI in Drug R&D: At Last, the End of the Beginning
With the emergence of AI as an increasingly dominant force in industry (and society), much of the early discussion around AI in biopharma has tended to treat it largely as an abstraction. Advocates and investors insist AI is a transformative superhuman technology poised to domesticate R&D, while cynics, including many grizzled drug hunters, tend to assume it’s just the latest in a long series of overhyped bright and shiny objects, destined first to distract, then to disappoint.
Jazz Scoops Up Epilepsy Drug, Boulevard Aims for Immune Reset, & AbCellera Matures
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more.
Genetic Medicines For Kidney Diseases: Jason Coloma on The Long Run
Jason Coloma is today’s guest on The Long Run. Jason is the CEO of South San Francisco-based Maze Therapeutics. The company is developing small molecule drugs to halt or potentially reverse kidney diseases. The drug discovery work at Maze is grounded in human genetics, looking at large pools of data to see how variants of one kind or another can make people sick, or protect them from falling ill.
Takeda Wins First-in-Class Orexin OK, Lilly’s Obesity Money Gusher, & Three New IPOs
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more.
LifeMine, In Verdine’s Big Year, Raises $263M For Safer Drug for Organ Transplants
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more.
J&J Buys In Vivo CAR-T, Sarepta’s New Boss, & Three IPOs in the Queue
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more.
Inhalable Medicines for Severe Lung Diseases: Lyn Baranowski on The Long Run
Lyn Baranowski is today’s guest on The Long Run. Lyn is the CEO of Boston-based Avalyn Pharma. The company is developing inhalable drugs for rare, severe lung diseases, such as pulmonary fibrosis and other interstitial lung diseases. Lyn Baranowski, CEO, Avalyn Pharma Avalyn has taken a couple of small molecules that are given orally, and remade them into inhalable drugs so they can be more effectively delivered where they need to go, deep in the lungs.
Dimension Hauls In $800M, Arrowhead Nails Triglycerides, Tempus Buys Personalis
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more.
Merck Oral PSCK9 OK’d, Vertex Snaps Up Crinetics, Lilly Buys a Psychedelic
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more.
A Schizophrenia Drug Patients Can Stick With: Heather Turner on The Long Run
Heather Turner is today’s guest on The Long Run. Heather is the CEO of New York-based LB Pharmaceuticals. It’s developing treatments for serious mental health disorders such as schizophrenia, depression, and bipolar disorder. Heather Turner, CEO, LB Pharmaceuticals The company is running late-stage clinical trials for its lead drug candidate, LB102. It’s a methylated derivative of amisulpride, a benzamide antipsychotic.
Useful Fictions or Distorting Frames? How Models Shape Drug R&D
We rely on models — deliberate simplifications — to navigate, make sense of, and engage productively with an ever-more complicated world. Patients understand their illnesses through what Dr. Arthur Kleinman called “explanatory models.” Physicians use models such as the pathophysiologic model or the biopsychosocial model to integrate their patients’ symptoms and fashion treatments. Biopharma R&D would be impossible without models as well.
Precision Cancer Drugs and Combos: Troy Wilson on The Long Run
Troy Wilson is today’s guest on The Long Run. Troy is the co-founder and CEO of San Diego-based Kura Oncology. The company, founded in 2014, has gone all the way through R&D to develop its own novel cancer drug. It’s called ziftomenib (brand name Komzifti). It’s an oral pill that inhibits a target called menin.
The Rise, Fall, and Rise (and Fall…?) of Cell and Gene Therapy
Carl Schoellhammer, partner, DeciBio More than $14 billion in announced acquisition value has flowed into in vivo cell therapy companies over the last 18 months. Lilly acquired Kelonia, AbbVie bought Capstan, BMS acquired Orbital, and AstraZeneca bought EsoBiotec, to name a few.
AbbVie Acquires Apogee, FDA Changes Tune on RegenxBio, & Merck Seizes TL1A Lead
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more.
Ollin Advances with $330M to Challenge Roche in DME & Wet AMD
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more.
Why Non GamStop Casinos Are Taking Over – And What That Means for You
Why Non GamStop Casinos Are Taking Over – And What That Means for You Walk into any online gambling forum lately and you’ll see the same thing: players frustrated with UKGC restrictions, hunting for something looser. That something is curacao casinos not on gamstop. These offshore platforms aren’t just a workaround-they’re a whole different animal. Bigger bonuses, fewer rules, and game libraries that dwarf what’s available under British regulation. The question isn’t whether they exist.
Kardigan Continues IPO Trend & FDA Reconsiders UniQure and Moderna
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more.
Small Molecules To Correct Disease: Sri Kosuri on The Long Run
Sri Kosuri is today’s guest on The Long Run. Sri is the co-founder and CEO of Emeryville, California-based Octant Bio. The company is developing oral small molecule drugs that are designed to correct protein misfolding and mistrafficking. Quite a few rare diseases, cancers, and metabolic disorders are thought to be amenable to this strategy.
Parabilis IPO Pops, J&J Buys More Degraders, & GSK’s Precision Oncology Bet
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more.
City Therapeutics Pockets $99.5M, Advances RNAi Candidates to the Clinic
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more.
Wellness Tech: Don’t Use as Directed
The Great Technology Plan for Wellness, to simplify only slightly, envisions a path to health that runs through data: collect more (through wearables and blood tests), analyze with AI, and deliver personalized coaching that improves as the data grow and the models sharpen. It sounds sensible, and one day it may even deliver — I’m long-term optimistic.
Show More
loading
Actions
Get in touch with Luke
Contact Luke, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack